TCR Biomarker Identification & Selection

• Bispecific TCR Development
• Drug Discovery Assay for Cytokine Storm Inhibition
• End-to-end CAR Hybrid TCR-T Cell Therapy Development
• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • scFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Service
  • CAR Cell In Vitro Assay Service
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trials
• TCR Modified T Cell Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Analysis
  • TCR Clinical Applications
• TCR-Like Antibody Services
  • MHC/Peptide Complex Production for TCR-Like Antibody Discovery
  • TCR-Like Antibody Discovery Strategies
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction and Evaluation Service
• Dendritic Cell Vaccine Development
  • Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells

TCR Biomarker Identification & Selection

Creative Biolabs offers the world leading custom TCR development service with the most advanced techniques and years of experiences to establish the solid platform for TCR production. Our technical experts are looking forward to designing a strategy of TCR biomarker identification & selection required for your assays and will be able to recommend an approach appropriate to your project needs.

Adoptive transfer of T cells gene-engineered with antigen-specific T cell receptors (TCRs) has proven its feasibility and therapeutic potential in the treatment of tumors. To ensure clinical development of TCR gene therapy, it is necessary to target immunogenic epitopes that result in optimal T cell fitness. Ideally, target antigens are selectively expressed by tumor tissue but not healthy tissue, and hence not expected to evoke a response against self. At the same time, target antigens should have proficient immunogenicity to initiate an effective anti-tumor response.

As the most basic foundation of therapeutic effect, these TCR biomarkers commonly possess the following principles:

• Target antigens should be expressed at high levels by most of tumor cells.
• Antigen cross-presentation may take part in the infiltration of antigen-specific CD8 T cells and cause activation of T cells and subsequent stroma destruction, thereby preventing outgrowth of antigen-negative tumor cells. Hence, the cross-reactive antigens must be excluded.
• Peptide epitopes that are cross-presented or the targeting of more than a single peptide is better choice.

Creative Biolabs provides our clients almost all the discovered cancer targets or other disease and novel ones in the evaluation for TCR therapy. Like CEA for colorectal, HER2 for breast cancer, BEV for Hodgkin lymphomas, STEAP1forEwing’s sarcoma, TOSO for rhabdomyosarcoma, SSX2 for synovial sarcomas, BMLF-1 for Epstein-Barr virus, gp41 for HIV, IE for cytomegalovirus, NS3 for hepatitis C virus, HBc18-27 for hepatitis B virus, VSV8 for vesicular stomatitis Indiana virus, etc. More than that, our experts have the best knowledge reserves and a wealth of research experience and the ability to discover new targets for our customers.

Fig.1 The Featured Target Marker of TCRs

Creative Biolabs has the capability to enable you to free up your time for core work and project. Our service can be designed to meet your special needs if you have any requirements. If you are interested in our service, please contact us by sending E-mail and our team will get back to you as soon as possible.

TCR biomarker identification & selection TCR generation & optimization TCR design & construction TCR gene packaging & delivery TCR-T in vitro assay TCR-T preclinical in vivo assay TCR-T clinical applications